Logo image of TELA

TELA BIO INC (TELA) Stock Fundamental Analysis

NASDAQ:TELA - Nasdaq - US8723811084 - Common Stock - Currency: USD

2.61  -0.06 (-2.25%)

After market: 2.6 -0.01 (-0.38%)

Fundamental Rating

3

Overall TELA gets a fundamental rating of 3 out of 10. We evaluated TELA against 189 industry peers in the Health Care Equipment & Supplies industry. TELA may be in some trouble as it scores bad on both profitability and health. TELA is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TELA had negative earnings in the past year.
TELA had a negative operating cash flow in the past year.
TELA had negative earnings in each of the past 5 years.
TELA had a negative operating cash flow in each of the past 5 years.
TELA Yearly Net Income VS EBIT VS OCF VS FCFTELA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

TELA has a Return On Assets of -78.32%. This is in the lower half of the industry: TELA underperforms 79.79% of its industry peers.
Industry RankSector Rank
ROA -78.32%
ROE N/A
ROIC N/A
ROA(3y)-59.43%
ROA(5y)-51.21%
ROE(3y)-240.76%
ROE(5y)-175.72%
ROIC(3y)N/A
ROIC(5y)N/A
TELA Yearly ROA, ROE, ROICTELA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

TELA's Gross Margin of 68.31% is fine compared to the rest of the industry. TELA outperforms 77.13% of its industry peers.
TELA's Gross Margin has improved in the last couple of years.
TELA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.63%
GM growth 5Y14.06%
TELA Yearly Profit, Operating, Gross MarginsTELA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TELA has more shares outstanding
Compared to 5 years ago, TELA has more shares outstanding
Compared to 1 year ago, TELA has an improved debt to assets ratio.
TELA Yearly Shares OutstandingTELA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
TELA Yearly Total Debt VS Total AssetsTELA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

TELA has an Altman-Z score of -9.09. This is a bad value and indicates that TELA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.09, TELA is not doing good in the industry: 78.72% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.09
ROIC/WACCN/A
WACC9.91%
TELA Yearly LT Debt VS Equity VS FCFTELA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.62 indicates that TELA has no problem at all paying its short term obligations.
TELA's Current ratio of 2.62 is in line compared to the rest of the industry. TELA outperforms 48.94% of its industry peers.
TELA has a Quick Ratio of 1.81. This is a normal value and indicates that TELA is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.81, TELA perfoms like the industry average, outperforming 45.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.81
TELA Yearly Current Assets VS Current LiabilitesTELA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

TELA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.96%, which is quite good.
The Revenue has grown by 29.36% in the past year. This is a very strong growth!
TELA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.86% yearly.
EPS 1Y (TTM)17.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)29.36%
Revenue growth 3Y47.51%
Revenue growth 5Y47.86%
Sales Q2Q%25.94%

3.2 Future

TELA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.08% yearly.
Based on estimates for the next years, TELA will show a very strong growth in Revenue. The Revenue will grow by 26.22% on average per year.
EPS Next Y33.46%
EPS Next 2Y29.7%
EPS Next 3Y23.37%
EPS Next 5Y19.08%
Revenue Next Year29.1%
Revenue Next 2Y27.29%
Revenue Next 3Y26.31%
Revenue Next 5Y26.22%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TELA Yearly Revenue VS EstimatesTELA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
TELA Yearly EPS VS EstimatesTELA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TELA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TELA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELA Price Earnings VS Forward Price EarningsTELA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELA Per share dataTELA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as TELA's earnings are expected to grow with 23.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.7%
EPS Next 3Y23.37%

More info and screens

0

5. Dividend

5.1 Amount

TELA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELA BIO INC

NASDAQ:TELA (2/11/2025, 8:00:01 PM)

After market: 2.6 -0.01 (-0.38%)

2.61

-0.06 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners72.25%
Inst Owner Change-34.16%
Ins Owners7.13%
Ins Owner Change3.68%
Market Cap102.81M
Analysts83.64
Price Target9.38 (259.39%)
Short Float %1.06%
Short Ratio2.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.88%
Min EPS beat(2)-5.93%
Max EPS beat(2)-1.82%
EPS beat(4)1
Avg EPS beat(4)6.95%
Min EPS beat(4)-19.5%
Max EPS beat(4)55.05%
EPS beat(8)4
Avg EPS beat(8)6.21%
EPS beat(12)4
Avg EPS beat(12)-1.13%
EPS beat(16)4
Avg EPS beat(16)-3.11%
Revenue beat(2)0
Avg Revenue beat(2)-7.98%
Min Revenue beat(2)-14.54%
Max Revenue beat(2)-1.41%
Revenue beat(4)1
Avg Revenue beat(4)-3.64%
Min Revenue beat(4)-14.54%
Max Revenue beat(4)1.66%
Revenue beat(8)1
Avg Revenue beat(8)-5.16%
Revenue beat(12)5
Avg Revenue beat(12)-2.95%
Revenue beat(16)7
Avg Revenue beat(16)-1.07%
PT rev (1m)0%
PT rev (3m)-14.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.06%
EPS NY rev (1m)0%
EPS NY rev (3m)5.82%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)9.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.5
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS1.74
BVpS-0.16
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.31%
FCFM N/A
ROA(3y)-59.43%
ROA(5y)-51.21%
ROE(3y)-240.76%
ROE(5y)-175.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.63%
GM growth 5Y14.06%
F-Score1
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.43%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.81
Altman-Z -9.09
F-Score1
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)117.65%
Cap/Depr(5y)170.23%
Cap/Sales(3y)2.57%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y33.46%
EPS Next 2Y29.7%
EPS Next 3Y23.37%
EPS Next 5Y19.08%
Revenue 1Y (TTM)29.36%
Revenue growth 3Y47.51%
Revenue growth 5Y47.86%
Sales Q2Q%25.94%
Revenue Next Year29.1%
Revenue Next 2Y27.29%
Revenue Next 3Y26.31%
Revenue Next 5Y26.22%
EBIT growth 1Y-10.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.11%
EBIT Next 3Y25.65%
EBIT Next 5Y26.05%
FCF growth 1Y-13.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.61%
OCF growth 3YN/A
OCF growth 5YN/A